Literature DB >> 20413544

Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils.

C M Gravett1, A J Theron, H C Steel, G R Tintinger, R Cockeran, C Feldman, R Anderson.   

Abstract

The research question addressed in the current study was: do formoterol (1 and 10 nM) and montelukast (2 μM) possess interactive inhibitory effects on activated human neutrophils, particularly in relation to alterations in cyclic AMP and cytosolic Ca²(+) fluxes? Isolated human blood neutrophils were activated with the chemoattractant N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) (1 μM) in combination with cytochalasin B (CB; 3 μM). Fura-2-acetoxymethyl ester-based spectrofluorimetry, lucigenin-enhanced chemiluminescence, colorimetric and flow cytometric procedures were used to measure cytosolic Ca²(+) fluxes, production of superoxide, elastase release and beta-2 integrin (CR3) expression, respectively, while cyclic AMP and leukotriene (LT)B₄ were assayed using competitive binding ELISA procedures. Activation of the cells with fMLP/CB resulted in abrupt and sustained increases in cytosolic Ca²(+), as well as release of elastase and production of superoxide and LTB₄, and expression of CR3, all of which were attenuated by formoterol and montelukast individually, and especially by the combination of these agents. These anti-inflammatory effects of each agent, as well as the combination, were associated with significant increases in cyclic AMP. The findings of the current study may explain the efficacy of montelukast and formoterol when used in combination with inhaled corticosteroids in the treatment of severe asthma, possibly by controlling neutrophil-driven inflammation of the airways.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413544     DOI: 10.1183/09031936.00157409

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Pharmacological approaches to regulate neutrophil activity.

Authors:  G R Tintinger; R Anderson; C Feldman
Journal:  Semin Immunopathol       Date:  2013-03-15       Impact factor: 9.623

Review 3.  Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease.

Authors:  Helen C Steel; Riana Cockeran; Ronald Anderson; Charles Feldman
Journal:  Mediators Inflamm       Date:  2013-12-25       Impact factor: 4.711

4.  Formoterol is more effective than salmeterol in suppressing neutrophil reactivity.

Authors:  Gregory R Tintinger; Annette J Theron; Helen C Steel; Charles Feldman; Ronald Anderson
Journal:  ERJ Open Res       Date:  2015-09-14

Review 5.  Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?

Authors:  Annette J Theron; Helen C Steel; Gregory R Tintinger; Charles Feldman; Ronald Anderson
Journal:  Drug Des Devel Ther       Date:  2013-11-22       Impact factor: 4.162

6.  The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro.

Authors:  Ronald Anderson; Annette J Theron; Helen C Steel; Chrisna Durandt; Gregory R Tintinger; Charles Feldman
Journal:  Mediators Inflamm       Date:  2014-03-06       Impact factor: 4.711

Review 7.  Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function.

Authors:  A J Theron; H C Steel; G R Tintinger; C M Gravett; R Anderson; C Feldman
Journal:  J Immunol Res       Date:  2014-05-25       Impact factor: 4.818

8.  Effects of β2-adrenergic agonists on house dust mite-induced adhesion, superoxide anion generation, and degranulation of human eosinophils.

Authors:  Yutaka Ueda; Kazuyuki Nakagome; Takehito Kobayashi; Toru Noguchi; Tomoyuki Soma; Katsuyo Ohashi-Doi; Kenichi Tokuyama; Makoto Nagata
Journal:  Asia Pac Allergy       Date:  2020-04-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.